Biogenica Laboratories LLC

Biogenica Laboratories LLC was paid $2.35M by Medicaid between Jan 2018 and Oct 2024, across 54 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 77% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#52 of 122

Median peer was paid$1.29M

This provider vs. median1.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,381	$56K
2019	4,435	$37K
2020	23,254	$755K
2021	31,608	$1.15M
2022	12,593	$345K
2023	674	$3K
2024incomplete	291	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	77%	28,945	22,698	$1.81M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	14%	18,697	14,241	$332K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.1%	3,190	2,964	$50K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.6%	3,455	3,291	$37K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.2%	3,034	2,781	$29K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.1%	522	488	$25K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	7,016	6,488	$21K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	584	573	$11K
81404		<1%	60	59	$5K
86769		<1%	314	314	$4K
81317		<1%	59	58	$4K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	80	80	$3K

42 more codes

81292		<1%	54	$3K
81321		<1%	54	$3K
81272		<1%	54	$1K
81298		<1%	57	$1K
80354		<1%	521	$1K
80370		<1%	516	$1K
81235		<1%	52	$1K
80321		<1%	237	$1K
80368		<1%	451	$871.29
80373		<1%	456	$758.86
80375		<1%	512	$734.72
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	19	$632.51
80372		<1%	455	$625.35
80377		<1%	452	$619.52
83992		<1%	582	$610.20
81295		<1%	57	$610.15
80360		<1%	451	$574.93
80366		<1%	257	$574.90
80355		<1%	257	$574.22
80361		<1%	532	$300.28
80364		<1%	525	$255.96
80358		<1%	526	$250.17
80359		<1%	463	$244.33
80365		<1%	522	$238.00
80367		<1%	466	$234.87
80348		<1%	520	$210.20
80324		<1%	519	$180.58
80337		<1%	236	$174.93
80356		<1%	462	$174.78
80347		<1%	513	$151.90
80353		<1%	518	$149.97
80352		<1%	230	$140.00
80349		<1%	116	$32.84
80335		<1%	241	$14.93
81407		0%	49	$0.00
81201		0%	49	$0.00
81211		0%	57	$0.00
81405		0%	49	$0.00
81403		0%	50	$0.00
81408		0%	49	$0.00
81406		0%	49	$0.00
81479	Unlisted molecular pathology procedure	0%	45	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLALEHZAR, DAVID (OWNER)